Field cancerization is a paradigm for tumorigenesis itself. Before the growth of a malignant lesion, a normal cell lineage can acquire pro-tumorigenic genetic mutations or epimutations (hereafter collectively referred to as 'mutations') that are positively selected for in the microenvironment of an otherwise healthy organ. Consequently, the mutant lineage, also referred to as a 'mutant clone' , can grow to produce large patches, or fields, of cells that are predisposed to eventually progress to a neoplasm (FIG. 1) . A cancerized field is a group of cells that are considered to be further along an evolutionary path towards cancer 1 . The microenvironment surrounding the mutant cells may also be abnormal and/or be altered by the cancerized field; the interplay between the mutant cells and their microenvironment determines which mutations are selected for. The field may or may not exhibit morphological change (for example, cancerized cells may look normal or could exhibit dysplasia). Field cancerization is interchangeably referred to in the literature as field effects or field defects.
There is evidence that cancerized field development, with or without overt morphological change, occurs across tissue types and throughout the body (TABLE 1) . The size of the cancerized field varies substantially, and a cancerized area of tissue will have a microscopic morphology classified as noncancerous, that is, normal, hyperplasia, metaplasia or dysplasia 2 . In a technical sense, the smallest cancerized field is a single lineage -even a single cell -that has evolved towards cancer but has not yet itself become malignant. Together, these data imply that every cancer arises from a potentially detectable cancerized condition.
Pre-malignant diseases -morphologically discernible conditions that increase cancer risk -are examples of field cancerization with associated morphological change. Pre-malignant disease is recognized in many different organs, perhaps most notably in Barrett oesophagus (BE) 3 , ductal carcinoma in situ (DCIS) in the breast 4 and prostatic intraepithelial neoplasia (PIN) 5 . These premalignant lesions all represent the growth of mutant lineages that are putatively further on an evolutionary path towards cancer. Because the removal of cancerized fields is often associated with substantial risk of morbidity, or even mortality (for instance, in BE 6 or inflammatory bowel disease (IBD) 7 ), they are typically left in situ, and watchful waiting (longitudinal surveillance typically with biopsy sample collection) is performed 8, 9 
.
Discerning the degree of cancerization of a field at the genetic level requires making the important -but challenging -distinction between mutant lineages and cancerized lineages. The former may have many somatic mutations that are inconsequential to tumorigenesis, whereas the latter will have mutations that, in an appropriate microenvironmental context, increase the rate of, or drive, cancer development. Mutations accrue steadily throughout life in ageing tissues 10 , and the neutral competition (drift) between the adult stem cells that maintains the tissue causes the clonal expansion of some of these mutants 11 ; therefore we could broadly consider all mutant cells to be cancerized, and then we would logically have to believe that the entire body becomes increasingly cancerized as it grows older. This definition is clearly not specific enough to be useful.
Rather, we here propose that a cancerized field is best described by its phenotypic properties. Our revised definition of a cancerized field is a collection of cells that have gained some but not all the phenotypic alterations required for malignancy; in general, this altered pheno type will have been caused by underlying mutation. These phenotypic changes could include properties such as an increased growth rate, decreased death rate or increased immune evasion; consequently, the pheno typic changes need not be morphological changes. These phenotypic changes will have been caused by mutations in key cancer-associated genes that act either autonomously or in tandem with an altered microenvironment. The field need not be monoclonal in origin. Moreover, this definition avoids the challenge inherent in prescribing importance to individual mutations.
We note that cancerized phenotypes may be subtle and/or transient. For instance, mutation of TP53 (which encodes p53) in the skin provides a survival advantagea cancerized phenotype -but this phenotype is evident only in response to ultraviolet exposure 12 . An initial mutation in the adenomatous polyposis coli (APC) tumour suppressor gene in the colon is clearly a step towards colorectal cancer (CRC), and cells within crypts with mono-allelic APC mutation show increased methy lation pattern diversity that is indicative of an increased size of the intestinal stem cell niche and/or increased stem cell lineage survival 13, 14 . Our phenotypic definition excludes regions of tissue having DNA damage or mutations that do not yet have a cancer-related pheno type, excluding even oncogene or tumour suppressor gene mutations that do not cause a cancer-related pheno type until additional mutations emerge. Nevertheless, we suspect that most, if not all, cancer-associated mutations will have phenotypic consequences in normal tissue -at least under particular environmental conditions -and furthermore that the altered pheno type of the cancerized lineage will be the mechanistic cause of its expansion. Consequently, a cancer arising from a field passes through multiple pheno type states, whereas the lineage leading to a sporadic tumour may not have had any phenotypic changes before cancer growth.
Inherited cancer risk -for example through the inheritance of a defective copy of a tumour suppressor gene -also leads to cells in the body being predisposed to cancer. We reserve the term 'field cancerization' to apply to only a somatic evolutionary process that produces cells that are 'closer to' cancer. Genetically mosaic disease, resulting from mutation and consequent pheno typic changes arising during development, is an intermediate example of field cancerization 15 .
In this Review, we discuss what combination of geno types and phenotypes constitutes a cancerized field, how such fields are initiated and how they expand, and end by considering the clinical implications of field cancerization.
A brief history of field cancerization Historical definition of a cancerized field. In 1953, Slaughter et al. first proposed the concept of field cancerization in order to explain the statistical enrichment of the multifocal (rather than isolated) oral squamous carcinomas they found in 783 patients with cancer 16 . The authors hypothesized that the patches of microscopically abnormal (but histologically benign) tissue surrounding the tumours suffered from the "preconditioning of an area of epithelium to cancer growth by a carcinogenic agent" (REF. 16 ). In the decades that followed, the advent of molecular biology fostered genetic analyses that revealed that fields of epithelial cells predisposed Figure 1 | Characterization and initiation of a cancerized field. a | A sporadic tumour is a lesion that does not share its tumorigenic mutations with surrounding tissue. The mucosa surrounding the tumour is typically morphologically and phenotypically normal. b | By contrast, a tumour growing in a cancerized field is one that began from a malignant cell that initially shared tumorigenic mutations and concomitant altered phenotype with the surrounding tissue; these alterations led to expansion of its ancestral lineage to form a field of cancer-primed cells. Within the field, the malignancy evolved because of additional mutations (and phenotypic change) in an evolving and potentially cancer-promoting microenvironmental context. The cancerized field of cells harbouring tumorigenic mutations may appear morphologically abnormal (for example, dysplastic) or normal, but the cells in the cancerized field will have an altered phenotype -such as increased survival -that underpins the expansion of the field. c | A cancerized field may be independently initiated by many cells following a mutagenic insult. Such an insult may provide cells with an advantageous phenotype as a direct consequence of DNA damage (for example, mutations caused by ultraviolet radiation) within a key gene and/or by providing an enabling microenvironment (for example, microenvironmental changes induced by cigarette smoke). These initiated cells, which occur in varying numbers, will clonally expand to create a (mostly) contiguous patch of cancer-primed cells. potential for demethylation and the likelihood of convergent epi genetic evolution mean that the clonality of the epigenetic fields is open to question. Instead, the cancerized field is likely to have formed because of exposure to a prevalent mutagen and promoter of clonal expansion (for example, in the case of the H. pylori-infected stomach) and/or subsequent convergent evolution of the epigenome (for example, in the case of synchronous CRC). Thus, field cancerization can occur because of multiple independent clonal expansions. Nevertheless, mutational diversity that exists within the cancerized field is likely a substrate for natural selection, and so over time, it is likely that the fittest clone (for example, that with the most adaptive phenotype) will come to dominate the field. Genetic drift will also shape the clonal composition of the field 20 . Related to this, others have suggested that exposures that have pleiotropic effects on cell phenotypes and microenvironmental inter actions across many organs -such as smoking -should be thought of as causing a body-wide 'aetiological field effect' (REF. 21 ) that is clearly not clonal in origin.
Alterations of stromal cells can also promote field cancerization. In the skin, epigenetic modification of fibroblasts is induced by ultraviolet exposure, leading to the production of diffusible growth factors, inflammatory cytokines and matrix-remodelling enzymes that together predispose to subsequent epithelial tumours 22 . In this particular example, the resulting epithelial tumours show recurrent genetic alterations, implying that the cancerized stromal compartment alone is unable to cause a tumour but provides selective pressure for particular epithelial genotype-phenotype combinations. Because the stroma does not transform into a tumour itself, here, we do not consider the stroma itself to be cancerized.
Field cancerization driver mutations. In cancer genomics, a distinction is commonly made between driver mutations, which confer growth or survival advantages on tumour cells (within the appropriate microenvironment) and passenger (neutral) mutations, which passively accumulate in cell lineages [23] [24] [25] . Borrowing that nomenclature, here, we term the mutations that are functionally important for the phenotypic changes that underpin the cancerized field 'field cancerization drivers' . We note that the phenotypic consequences of a driver mutation may be context dependent, so simply having a field cancerization driver may not be sufficient to cause a phenotypic change in the current microenvironmental condition.
In skin (squamous epithelium), putative field cancerization driver mutations are found in genes, including Notch family members and TP53. Mutations in these genes are detected at high frequency in apparently normal sun-exposed skin cells 26 . Mouse models show that Notch family mutants are clonally selected for in oesophageal squamous cell epithelium owing to their ability to inhibit differentiation 27 . TP53 mutation has been long recognized to be present in nondysplastic skin, and its frequency increases with age 28 and causes an increase in the stochastic growth rate of the clone, but only in the presence of chronic ultraviolet exposure 12 . Similarly, lineage tracing in mice has shown that Hedgehog pathway mutations are positively selected for in skin because they inhibit differentiation 29 . Remarkably, the density of clonally expanded putative driver alterations in skin was estimated at ~140 driver mutations per square centimetre 26 -for example, more driver mutations can be found in a small patch of morphologically normal skin than in a skin basal cell carcinoma 30 .
In the inflamed intestine, mouse models show that Trp53 mutation is a field cancerization driver because it increases stem cell replacement in a chronic inflammatory setting . To determine precisely which mutations are field cancerization drivers requires in vivo lineage tracing, preferably in both model systems and human tissues. Such model systems can reveal the mechanism that provides a clone with a selective advantage (as per the above examples). Nevertheless, we note that the exact phenotypic consequences of many putative cancer driver mutations remain elusive, and their common occurrence in cancers may in fact be because the driver is selected for before overt cancer growth, that is, during field cancerization. In cancers, broadly speaking, a mutation will be called a driver if it occurs more frequently across tumours than is expected from the mutation rate alone 34 -the excess frequency is then a consequence of positive selection for the mutation. However, this analysis does not show when during the tumorigenic process the driver mutation was positively selected for or if it is still under positive selection within the tumour at the time it is observed. In other words, the so-called cancer driver may not actually drive cancer growth per se but rather had previously driven the growth of an ancestral lineage. Recognizing that driver mutation selection is inherently context-dependent and, moreover, that the context changes over time provides a Box 1 | Pre-malignant disease: a resource for cancer evolution studies Fortuitously for the research community, the clinical practice of watchful waiting for pre-malignant lesions leads to extremely well-characterized longitudinal tissue catalogues that facilitate the temporal study of clonal evolution in situ in humans. Such study can reveal the pace and pattern of cancerized clone evolution and/or phenotype generation and spread 109, 134 , and this information can be directly leveraged to optimize biomarker development and screening regimens 135 . The exciting multi-institution Pre-Cancer Genome Atlas (PCGA) aims to compile a comprehensive characterization of the molecular alterations in pre-malignant lesions as well as, importantly, the corresponding changes in the microenvironment and cellular phenotypes 136 . It is also crucial that the PCGA contains longitudinal data so that the context-specific nature of cancer evolution and the concomitant intricacies of the genotype-phenotype mapping, together with the critical rates of cancer evolution, can be fully elucidated.
Epistasis
The interaction of multiple genes that leads to the development of a phenotypic trait.
Polyclonal
An attribute of a lesion that is derived from two or more clones as opposed to a monoclonal origin.
convenient explanation for the high frequency at which prominent cancer-related genes are found in cancerized fields 35 . We also note that in some instances, the same phenotype will be positively selected for in both the cancerized field and in a cancer itself: for example, functional TP53 mutations appear to drive cancerization of the inflamed intestine 31 , likely because they provide a survival and/or growth advantage, and these same phenotypes are clearly also important for subsequent cancer development 36 . Hence, a field cancerization driver may also be a cancer driver.
Progression to cancer likely involves the accumulation of multiple field cancerization driver mutations 37 . Phenotypic change is caused by either individual high-impact mutations or epistasis among a synergistically acting group of mutations, each of which would be insufficient to cause a change to a cancerous phenotype without the others. Alternatively, progression may be caused by sudden large-scale mutational events that simultaneously alter large parts of the genome and elicit large phenotypic change: whole-genome doubling appears to apply a transformative role in BE, for example 38, 39 . If mutations accrue gradually, then conceivably, the field cancerization driver burden can be used to identify patients at risk of progression, whereas predicting the likelihood of such 'catastrophic' events presents a larger challenge.
Mapping genotype to phenotype. Nuances in cell morphology and behaviour mean that cells within a cancerized field have phenotypes that theoretically occupy an infinite phenotype space, where position in phenotype space is determined partly by the underlying genotype (FIG. 2) . Understanding the genotype-phenotype map is critical for understanding the biology and evolution of cancerized fields. The example of TP53 and other driver genes given above shows that the genotype-phenotype map is many-to-many (there is one or more genotype that underlies each phenotype, but a genotype may incur different phenotypes on the basis of nongenetic effects); hence, the notion of a 'genetic blueprint' that entirely determines the biology of a cancerized field is overly simplistic. Pathological diagnosis categorizes the morphological features of pre-malignant disease into a small number of groups (for example, grade) -see TABLE 1. However, we note that the underlying multivariate nature of genotypes and phenotypes means that such classifications are in fact continuous and fluid. This continuity perhaps explains some of the evident challenges in reliably identifying particular pre-malignant states, such as a low-grade dysplasia in BE 40, 41 .
Initiation of the cancerized field
Cancerized fields may be induced by 'unlucky mutations' 42 that occur owing to natural DNA replication errors during ageing 43 or by mutagenic insult (FIG. 1c) . Immediately following the mutagenic insult, the mutated field will be composed of many genetically distinct clones, but over time, we expect that the clones with the fittest phenotypes will come to dominate the cancerized field 44 . If the mutagenic insult is ongoing, perhaps because it is caused by a persistent environmental factor such as tobacco carcinogens, diet or infections 21 , then new clones will be continually generated, and the field will continue to appear genetically mosaic.
For example, mutant cancerized fields, often bearing mutations in TP53, are seen in the lung and airways, and these mutations are associated with smoking exposure 45, 46 . In the cervix, high-risk strains of human papillomavirus impair normal p53 function, a condition that is likely permissive for the development of a field of preinvasive cervical intraepithelial neoplasia 47 . H. pylori infection is associated with field cancerization via intestinal metaplasia in the stomach 48 , but recent wholegenome sequencing on 100 gastric tumours found no association with mutational spectrum and H. pylori infection 49 ; this suggests that infection induces intestinal metaplasia fields via a nongenetic route, perhaps by providing a selective pressure for atrophic gastritis-resistant clones that bear epigenetic changes. This intriguing result highlights the need for further study to elucidate the role(s) of H. pylori infection in the formation of cancerized clones in the stomach. In the oesophagus, gastroesophageal reflux disease (GERD) increases the risk of oesophageal adenocarcinoma 50 , and a mutational signature thought to be characteristic of acid exposure is observed in the genomes of these cancers 51 , implying that the cancer arose from a field mutationally affected by GERD.
Accelerated ageing -the increase in the rate of events attributable to ageing -is implicated in tumorigenesis in many tissues. Indeed, the majority of high-frequency mutations found in a cancer (of which there are typically very many) is thought to accrue before the initiation of tumour growth 52 , and it seems likely that these would often be within a cancerized field. In patients with ulcerative colitis, mutational signature analysis 53 , CpG island hypermethylation 54 and telomere shortening 55 have indicated accelerated ageing in the colon. Utilizing epigenetic drift as a molecular clock shows that the ages of BE tissue vary dramatically between patients of similar chronological age 56 . Moreover, just as chronological age is recognized as one of the strongest predictors of cancer risk, biological tissue age (that is, the time a tissue has had to accrue additional stochastic alterations) contributes to field cancerization, and particular attention should be given to exploring its roles in neoplastic progression 57 . It is noteworthy that some early neoplastic lesions, such as adenomas in the colon 58 and nevi in the skin 59 , are derived from multiple independent clones -that is, the neoplastic lesions are polyclonal in origin 2 . While the mechanism that causes this polyclonality is unknown, a localized field defect provides a compelling explanation: an initial mutant clone may produce some kind of field (through aberrant signalling, for example) that alters the behaviour of surrounding stromal cells, creating an environment that in some way promotes mutations in neighbouring cells 60 . Indeed, in the colon, transformed intestinal crypts have profound effects on neighbouring wild-type crypts 61, 62 . Physical compression of intestinal mucosa induces WNT pathway signalling, and so the signalling induced by an initial expanded mutant clone can result from mechanical cues rather than juxtacrine or paracrine signalling 63 . Thus, the multitude of interactions between clones is important in the establishment of cancerized fields.
Mechanisms of clone growth
Human epithelia are organized into two broadly different types, glandular and squamous, and we discuss how clones grow in each epithelium type below. Tissue architecture constrains evolution by limiting the ability of mutant clones to expand and in so doing lengthens the waiting time to cancer 64 . Glandular epithelium. In order for a clone to grow in glandular tissue, such as intestine and BE mucosa, it must first undergo niche succession, whereby a mutant stem cell in the gland replaces all other stem cells (and so subsequently, all differentiated cells in the gland will also be mutant); second, the repopulated mutant gland must produce a field of mutant glands by gland fission 13, [65] [66] [67] (FIG. 3) . The unit of selection in glandular tissue therefore switches between individual stem cells within a gland to the meta-population of the gland as a whole (the differentiated cells in the gland are the somatic lineage derived from the germ stem cells Nature Reviews | Cancer in the gland). Measurement of gland division rates and the impact of tumorigenic mutations upon the rate are generally lacking. In the healthy colon, gland fission rates are very low -once every few decades 13 -and so it is clear that a field cancerization driver mutation that clonally expands to form a large patch of glands can do so only by causing a large increase in the fission rate.
Squamous epithelium. Epithelial cells within squamous tissue, such as epidermis, cervical, squamous oral and oesophageal squamous mucosa, expand by basal replacement of neighbouring stem cells 12, 27, 68, 69 . During normal homeostasis, basal cells proliferate, producing differentiated progeny that go on to form the superficial layers of the epithelium and also new basal cells that compete neutrally to grow a patch by the lateral replacement of one progenitor cell by another 70 (FIG. 3) .
Tumorigenic mutations, such as in TP53 and Notch family genes, tilt the competition in favour of the expansion of mutant clones 12, 27 (detailed above). Localized clonal expansion is the canonical mechanism of mutant field formation, but there may also be noncanonical methods. Long-range stem cell replacement occurs in the Drosophila ovaries 71 , and similar within-organ metastasis could occur in the human body: distant engraftment of genetically labelled organoids in the intestine provides a proof-of-concept of such a mechanism 72 . High-resolution lineage tracing studies 73, 74 where there is ongoing frequent genetic labelling that provides finer resolution of individual somatic lineages are required to reveal the frequency of long-range stem cell migration that is possible in both glandular tissue and squamous tissue.
What is selected for? Broadly speaking, phenotypes associ ated with increased growth and/or increased survival will be positively selected for. In squamous lesions, cells that are best able to adhere to the basement membrane will have increased survival because the lineage will not migrate and differentiate, whereas fasterproliferating basal cells have more opportunities to replace neighbouring cells. Similarly, in glands, upregulation of crypt fission (for example, with clonal expansion) and increased ability to survive environmental insult are traits expected to be under selection.
In the noninflamed colon, KRAS mutation accelerates the rate of crypt fission and is therefore selected for 75 . The cycles of wounding and repair that occur in the colonic mucosa of individuals with IBD are expected to provide a strong selective pressure, first for clones that can survive the damage and then for fast-proliferating clones that can rapidly heal the wound 76 . This selection within the cancerized field provides a ready explanation of the genetic differences between sporadic and colitisassociated CRC 53 . BE cells produce mucins that provide protection against insult from gastric acid reflux; hence, BE may be an adaptive response that is selected for in response to reflux 77 . Indeed, mathematical modelling of oesophageal adenocarcinoma progression suggests that age-dependent GERD symptoms affect not only BE onset but also proliferation rates of high-grade dysplasia due to acid-induced injury 78 . Together, these examples show how field cancerization represents an evolutionary trade-off between wound repair and cancer development: faster-healing wounds may come at the cost of field cancerization.
The mutation burden of apparently healthy tissues increases with age 10 -and consequently, aged epithelia are a patchwork of different clones. Clonal competition, or other interactions between these clones, may have an important influence on progression to cancer 79 . Clonal competition in general slows adaptation, so it may have a cancer-suppressive effect 64, 80 .
Role of the tissue microenvironment
Stromal reprogramming is increasingly recognized to play a critical role in tumorigenesis 81 . In general, the stromal microenvironment is a key regulator of self-renewal in the epithelium 82 , and so aberrant changes in the stroma can enable field cancerization of the epithelium.
Aberrant stroma (measured by fibroblast phenotypes and immune cell population composition) is indeed found in pre-malignant disease. For example, patients with IBD are at higher risk of CRC, and the severity of inflammation is an independent predictor of cancer risk 83 . In BE, the stromal compartment shows consistent changes in gene expression that also have prognostic value, and moreover, these changes are somewhat similar among pre-malignant conditions along the gastrointestinal tract 84 . In skin, loss of Notch family signalling in the mesenchymal cells of transgenic mouse models induces epithelial tumorigenesis, demonstrating how stromal changes enable field cancerization 22 . In the breast, transgenic manipulation and cancer-associated fibroblasts have revealed a critical role for the stromal lineage in . The genotypephenotype map guides the evolutionary path of cells in the two abstract infinite spaces of the genotype and phenotype. Progression from normal to a field-cancerized state and eventually to cancer is underpinned by changes in genotype; these changes are due to random somatic mutation (black filled arrows to pink points) that is then projected by the genotype-phenotype map, which incorporates cells' genetic mutations, epimutations, and microenvironmental context to produce a specified phenotype (dashed lines to orange points). Natural selection acts in the phenotype space to shift the predominant phenotype of the clone population to one of higher (contextual) fitness (dashed lines with unfilled arrowheads to purple points). Pink ovals represent regions of similar phenotype (N, normal tissue; M, metaplasia; H, hyperplasia; D, dysplasia; C, cancer). The genotype of fit parents is deterministically preserved back in genotype space (dashed lines to blue points). The diagram highlights the overlap in defined phenotypic regions -for example, some genotype-phenotype combinations could be histologically classified as either metaplastic or dysplastic. b | Punctuated evolution. Here, in contrast to the gradual phenotypic evolution of part a, the ostensibly normal clone carries a TP53 mutation, which then undergoes wholegenome doubling (WGD) and causes a large change in both genotype and phenotype, as has been seen in BE. c | Small changes in genotype space may also lead to large changes in phenotype space, possibly owing to rare variants having large phenotypic effects, epistatic effects between accumulated mutations and/or other epigenetic or microenvironmental effects. For example, a TP53 inactivating mutation may occur in a morphologically normal clone but not be selected for until subsequent small events accumulate to promote large phenotypic changes. In summary, the degree of phenotypic change need not be proportional to the degree of underlying genetic change. CDKN2A, cyclin-dependent kinase inhibitor 2A; SMAD4, mothers against decapentaplegic homologue 4. modulating epithelial cell behaviour 85, 86 . Moreover, in the colon, for example, genome-wide association studies for CRC have identified bone morphogenetic protein (BMP) family members that are regulated and expressed by stromal cells as key modulators of cancer development risk 87 . Microenvironmental changes enable field cancerization in the stroma by altering the fitness effects of mutations in epithelial cells (reviewed in REF. 88 ) and so promote expansion of cancerized lineages. Microenvironmental factors provide selective pressures for phenotype adaptation: within the cancerized field, cells explore the adaptive landscape (via genetic mutation or phenotypic plasticity), and the genotypes of future generations reflect the phenotype that successfully surmounted any microenvironmental challenges (FIG. 2) . From this theoretical 'fitness landscapes' perspective, Gatenby and Gillies proposed a model that identified six such micro environmental barriers for the development of a malignant phenotype: apoptosis with loss of basement membrane contact, inadequate growth promotion, senescence, hypoxia, acid osis and ischaemia 89 . Growth, senescence and cell death are clearly also influenced by cell-intrinsic factors (for example, oncogenic mutations) but, nevertheless, can also be regulated by intercellular signalling (that is, by the microenvironment) 90 . It is not simply serendipitous that a cancerized clone is found in a particular ecosystem -clonal adaptation can occur only owing to the current selective microenvironment.
Clinical implications
The key clinical issue presented by field cancerization is that of accurately determining the risk of cancer development from a cancerized lesion, as putatively cancerized fields are very common but few actually progress to cancer. Thus, simply assuming that the detection of a cancerized field is evidence of likely cancer development carries the hazard of overdiagnosis of cancer risk, and moreover, subsequent interventions to ameliorate the risk in most cases constitute overtreatment (with associated risks of unnecessary morbidities) 91 . Take the blood, for example: 1% of all newborn babies have cells with an acute lymphoblastic leukaemia-associated mutation and histopathologically identifiable precursor lesions that are present at ~100 times the corresponding rates of clinical cancers 92 , and moreover, such early genetic events can be shared between monozygotic twins, indicating that the pre-malignant clone formed in utero 93 . However, bone marrow transplant to remove the cancerized field would seem obscene, given that the intervention is unnecessary in 99% of patients. In adults, 10% of unselected individuals over the age of 65 show clonal expansion of cancer-associated mutations in their blood 94 . This apparent field cancerization in the blood increases cancer risk 13-fold 94 , in this case indicating that detection of a cancerized field is a biomarker of cancer risk. Nevertheless, the absolute risk of haematological cancer development in those patients with clonal haematopoiesis was still found to be very small (~1% annual incidence rate) 94 , so detection of the field itself will overdiagnose cancer risk in the majority of people. Clearly, there is an acute need for biomarkers that can distinguish cancerized fields that will remain indolent for a long time from those that will rapidly become malignant.
The pitfalls of pathology. Conventional pathologic grading remains the most common biomarker of cancer risk in conditions associated with field cancerization (for example, IBD and BE) and in morphologically discernible pre-malignant disease (for example, DCIS or PIN), but in general, the predictive value of pathological staging of pre-malignant disease is low. For instance, nondysplastic BE has been estimated to incur an ~0.25% annual risk of progression to adenocarcinoma 95 , whereas high-grade dysplasia carries a near 25-fold increase in risk at ~6% annual risk of progression 96 ; however, this still means that more than nine out of ten patients with BE who are diagnosed with a dangerous high-grade lesion will not progress to cancer in the next year. The annual risk of squamous carcinoma of the skin in patients with actinic keratosis ranges between 0.15 and 80%
97
, and published estimates of annual cancer incidence in patients with BE who have low-grade dysplasia range between 0.15 and 36%
98
. This tremendous variability is due to a multitude of factors, including interobserver variability in grading 99 , sampling bias (higher-grade lesions may be missed at biopsy 100 ) and patient cohort differences 97, 98 . Moreover, given that field cancerization can occur without associated morphological change, evidence of evolution along a trajectory towards cancer cannot reliably be assessed by pathology alone. Molecular biomarkers. Molecular profiling for sensitive detection of cancerized fields at high risk of developing malignancy is highly desirable
. As for molecular prognostication of established cancer, the ideal is to find a particular (small and easily assayable) set of molecular features (mutation status, RNA expression and/or protein level) that predict those patients at risk of progression with high sensitivity and specificity. For example, a number of different molecular panels show predictive value for oesophageal adenocarcinoma in patients with BE [101] [102] [103] and for lung cancer in current or former smokers 104, 105 . In the lung, gene expression within the proximal airway indicates distal cancer, perhaps as a direct consequence of a cancerized airway 105 . Unfortunately, the studies using such panels typically find that the nega tive predictive value is low; the panels are only moderately successful at predicting which patients will not get cancer in the future. While increasing the size of the biomarker panels may increase their predictive accuracy, panel size alone will not address the complicating factors of inter patient heterogeneity (not all patients will follow the same molecular path to cancer, so a rare dangerous path may not be assayed by the biomarker panel) and intra patient heterogeneity (whereby a biopsy may fail to sample a dangerous lesion).
Instead, we emphasize that biomarkers based on quantification of the underlying evolutionary process occurring within the cancerized field (rather than on measurement of a molecular feature that may or may not be an outcome of that process) may have pan-tissue prognostic value that is robust to the problem of interpatient and intrapatient molecular heterogeneity 106 . One such 'evolutionary biomarker' is the degree of genetic diversity within the cancerized field. Genetic diversity is a proxy measure of field evolvability, as a more diverse field is more likely to contain a lineage that is preadapted to a new selective pressure 107 . Indeed, genetic diversity has been shown to be prognostic in two different cohorts of patients with BE, even when using different molecular tools to quantify the diversity present 38, 108, 109 . The potential utility of clonal diversity as a prognostic measure across disease types was underlined by a recent pan-cancer study 110 . Similarly, genetic instability, as another measure of evolvability, has prognostic value in BE 111 and potentially also in colitis 112 . A second evolutionary measure is the size of clonal expansions, as this provides both a proxy assay for the size of the cancerized field and evidence for positive selection of clones within the field. Detection of clonal expansions has prognostic value in ulcerative colitis 113 and BE 111 and in the blood 94 . Similarly, changes in lesion composition over time could have prognostic value as a marker of active evolution of the field; quantification of the mutation rate (a proxy measure of the rate at which new adaptive lineages are produced) and rates of clonal expansion (how quickly a new high-cancerrisk clone grows to a large size) may hold particular prognostic value.
Optimizing screening schedules. The intervals between cancer screens may be optimized using knowledge of the biology of cancerized fields. If a field is rapidly evolving, then frequent screening may be required, whereas evolutionarily quiescent fields could be surveyed less often. For instance, in BE, longitudinal measurement of the clonal composition has revealed that little evolution occurs over time, and consequently, the level of genetic diversity within the BE segment -as an indicator of cancer risk -is also invariant over time 109 . Refinement of screening schedules and associated prognostic biomarkers requires longitudinal studies of the evolution within cancerized fields. Mathematical modelling of the underlying disease aetiology may further help to optimize the precise timing of clinical screens to maximize the probability that an individual is screened within a window of opportunity for timely intervention; here, evolutionary-minded approaches that explicitly model clonal expansions show particular promise [114] [115] [116] [117] [118] [119] . Chemoprevention. Part of the mechanism of action of chemopreventive therapies is likely to be through their modulation of pretumour field dynamics. Though direct evidence of this is generally lacking -owing to the difficulty inherent in studying pretumour clones -studies in BE provide a rare but elegant example. Therein, the cancer-reducing effects of non steroidal anti-inflammatory drugs (NSAIDs) 120 may occur because they can reduce the mutation rate and change the microenvironment such that certain clones that are already established in the tissue will no longer be selected for 121 . Similarly, we hypothesize that 5-aminosalicylate anti-inflammatory drugs reduce the risk of CRC in IBD 122 through similar mechanisms, and more generally, the chemopreventive effects of aspirin 123 are likely to function through the modulation of pre tumour field evolution. Proton-pump inhibitors used by patients with BE may also influence the formation of mutant clones, although the relationship, if any, to cancer progression remains unclear 124 . Further, the cancer-preventive effects of Bacillus CalmetteGuérin therapy for patients with superficial bladder cancer [125] [126] [127] may occur because it modulates clonemicroenvironment inter actions 128 . Understanding the mechanisms by which field cancerization drivers are selected for is a promising route towards the development of new chemopreventive drugs.
Box 2 | Deriving biomarkers for cancer risk prediction
Traditionally, tissue morphology has been used as the sole indicator that a patient has a certain risk of developing a malignancy. More recently, the presence or absence of particular molecular features has been used as a biomarker. However, measures of the evolution of the cancerized field itself, such as genetic diversity 107 , may also act as biomarkers for the risk of cancer development. Measuring the field as a whole removes the risk of sampling bias. Serial sampling and spatially extensive sampling in longitudinal analyses 38,109 will continue to provide better insight into the pace of evolution and thus aid prognostication.
Below, we provide a table of cancer biomarker types alongside a few of their benefits, pitfalls and examples.
Biomarker Benefits Pitfalls Examples
Tissue morphology Surgical interventions. The prospect of field cancerization within a patient undergoing cancer resection has implications for deciding surgical margins -should an entire cancerized field be removed along with the overt lesion? If field cancerization is commonly found in a certain disease, it is logical to think that patients will be at risk of metachronous tumours if the cancerized field is not removed along with the cancer itself 32, 114, [129] [130] [131] . In colitis, there has been a recent tendency for endoscopic (limited) resection of dysplastic pretumour lesions, which may underpin a slight increase in cancer incidence rates 100, 132 . As seen in the treatment of DCIS with breast-conserving surgery rather than mastectomy 133 , choosing optimal resection margins requires balancing the competing risks of morbidities associated with more radical surgery with the increased risk of rapid recurrence from a cancerized field left in situ. The development of an imaging modality to visualize the cancerized field during surgery has the potential to be revolutionary.
Summary and conclusions
The balance of evidence suggests that some tissues in our bodies inevitably, and unfortunately, become cancerized as we age: mutations accrue throughout life, and some will be unlucky mutations that drive the formation and phenotypic evolution of a field of mutant cells that is 'one step closer' to malignancy. Understanding the evolutionary dynamics of cells within these cancerized fields is key to identifying and then controlling those tissues that have aged ungracefully towards cancer.
